Ablation reduces the fre- quency of recurrent VT, although 27% to 55% have at least 1 recurrence; ablation of VT in arrhythmogenic right ventricular cardiomyopathy patients does not eliminate the need for an ICD in appropriate candidates. The potential risk of VT recurrence due to disease pro- gression should be reviewed with patients when considering ablation. There are no randomized comparisons of antiarrhythmic therapy to sup- press recurrent VT. Beta blockers, sotalol and ami- odarone have been used.S7.3-15 In an observational series, sotalol suppressed inducible VT in 58% of patients with <10% of patients experienc- ing arrhythmia recurrence during follow-up.S7.3-48 Effectiveness of the different medications appears to be variable, and so more studies are needed. 10. In arrhythmogenic right ventricular cardiomyop- athy, areas of fibrofatty scar in the RV free wall create areas of delayed ventricular activation causing fractionated deflections following the QRS, known as epsilon waves on the surface ECG (a major criterion) and late potentials in the signal averaged ECG (minor criterion) in the 2010 Task Force Criteria for diagnosis of arrhythmogenic right ventricular cardiomyopathy.S7.3-6 When the standard ECG QRS duration is 110 ms, criteria for abnormal signal-averaged ECG include any 1 of the following: filtered QRS duration 114 ms, duration of the terminal QRS <40 uV exceeding 37 ms, or a root mean square voltage in the terminal Abnormal findings on sig- nal averaged ECG correlated with disease severity on cardiac MRI,S7.3-35 and increased adverse events In an assessment of the diagnostic use of testing for arrhythmogenic right ventricu- lar cardiomyopathy, signal averaged ECG was of greater value than cardiac MRI or biopsy.S7.3-14 11. The value of an electrophysiological study is uncer- tain in asymptomatic arrhythmogenic right ven- tricular cardiomyopathy patients with preserved ventricular function in predicting subsequent risk for SCD. 